RESEARCH USE ONLY. Reference data for laboratory research. Not medical advice; not for human consumption.
Peptijournal
Calc
← Directory

Protocol Single compound

AOD-9604

hGH fragment 176-191 analog

Modified C-terminal fragment of human growth hormone studied in lipid-metabolism research.

Compare side by side →
Metabolic / Weight

Laboratory reference · in vitro research data

Research vial sizes
2 mg · 5 mg
Dosing data
Not listed — reference entry covers vial concentration only.
Storage
Powder: 2–8 °C, or −20 °C for longer storage. After mixing with BAC water: 2–8 °C, use within about 4 weeks.

Reconstitution concentrations

Concentration per BAC-water volume; 10 units = 0.1 mL on a U-100 syringe.

VialBAC watermg/mLmg per 10 u
2 mg1 mL20.2
2 mg2 mL10.1
2 mg3 mL0.670.067
5 mg1 mL50.5
5 mg2 mL2.50.25
5 mg3 mL1.670.167

Calculate your vial

Add reminder

Enter your own schedule. Saved only on this device — never sent anywhere.

Research use only — educational reference, not medical advice. This line is added to every reminder.

Works with iPhone Calendar, Google Calendar and Outlook.

Saved only in this browser. My reminders

Inputs
mg
mL
1 mg = 1,000 mcg
mg

Draw to

—units

= — mL on a U-100 syringe

Concentration
—
Per unit
—
Doses / vial
—
Syringe
01020304050607080901000.0u
U-100 · 100 units (1 mL)2 unit per line

Research dossier · published literature summary

01

Mechanism of action

AOD-9604 is a modified fragment of the C-terminal region of human growth hormone, developed to study fat metabolism without growth hormone's growth-promoting effects.

02

Observed research endpoints

  • It was developed by Metabolic Pharmaceuticals as a potential obesity treatment and had reached phase IIa trials by February 2002.
  • A 2026 sports-medicine review groups it with unapproved peptides that look favourable in animal models but have scarce rigorous human safety data.

03

Regulatory & safety context

  • Not approved by the FDA or EMA for any indication; research-grade material is not a medicine.
  • Listed as prohibited in sport by the World Anti-Doping Agency.
  • Reviewers warn of potential for serious harm when unapproved peptides are used outside regulatory oversight.

04

Citations

  1. Wilding J. AOD-9604 Metabolic. Curr Opin Investig Drugs. 2004;5(4):436–440.2004-04Drug development reviewRead paper ↗
  2. Mendias CL, et al. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026;56(8):1921–1935.2026-08Narrative reviewRead paper ↗

Keep exploring

Where researchers source it

Listings are provided for reference — always verify the latest third-party COA before purchasing.

Medvinci Research

See site

Featured supplier · third-party tested, COA published per batch

View product View COA

Supplier B

TBD

Placeholder — details coming soon

View productView COA

Supplier C

TBD

Placeholder — details coming soon

View productView COA